| JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies CEJ Downes, BJ McClure, DP McDougal, SL Heatley, JB Bruning, ... Frontiers in Cell and Developmental Biology 10, 942053, 2022 | 23 | 2022 |
| Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia CEJ Downes, BJ McClure, JB Bruning, E Page, J Breen, J Rehn, ... NPJ precision oncology 5 (1), 75, 2021 | 18 | 2021 |
| Identification of a novel GOLGA4–JAK2 fusion gene in B‐cell acute lymphoblastic leukaemia CEJ Downes, J Rehn, SL Heatley, D Yeung, BJ McClure, DL White British Journal of Haematology 196 (3), 700-705, 2022 | 5 | 2022 |
| Acquired mutations within the jak2 kinase domain confer resistance to jak inhibitors in an in vitro model of a high-risk acute lymphoblastic leukemia CEJ Downes, BJ McClure, J Rehn, J Breen, JB Bruning, DT Yeung, ... Blood 136, 5-6, 2020 | 2 | 2020 |
| Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia LN Eadie, JA Rehn, J Breen, MP Osborn, S Jessop, CEJ Downes, ... Genes 14 (2), 264, 2023 | 1 | 2023 |
| P-284 Elevated Desmoglein-2 Surface Expression Is an Independent Predictor of Poor Outcome in Multiple Myeloma C Toomes, B McClure, G Best, L Ebert, K Vandyke, M Cockshell, T Day, ... Clinical Lymphoma Myeloma and Leukemia 24, S199-S200, 2024 | | 2024 |
| Precision Medicine Approaches for JAK2-Rearranged Acute Lymphoblastic Leukaemia: The Efficacy of Targeted Therapies and Molecular Mechanisms of Drug Resistance CEJ Downes | | 2022 |
| Acquired mutations within the JAK2 kinase domain confer resistance to JAK inhibitors in in vitro models of acute lymphoblastic leukaemia C Downes, B McClure, J Bruning, J Breen, J Rehn, D Yeung, DL White Blood 2021 Annual Scientific Meeting, 2021 | | 2021 |
| Acquired Mutations within the JAK2 Kinase Domain confer Resistance to JAK Inhibitors in in vitro Models of High-Risk ALL CEJ Downes, BJ McClure, JB Bruning, J Breen, JA Rehn, DT Yeung, ... European School of Haematology (ESH) 2nd Translational Research Conference …, 2021 | | 2021 |
| JAK2 kinase domain mutations confer resistance to JAK inhibitors in a pro-B cell model of a high-risk acute lymphoblastic leukaemia CEJ Downes, BJ McClure, JB Bruning, SL Heatley, CH Kok, TP Hughes, ... Australian Society for Medical Research South Australian Scientific Meeting …, 2019 | | 2019 |
| Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk JAK2 fusion in B-cell acute lymphoblastic leukaemia CEJ Downes, BJ McClure, B Mayne, JB Bruning, SL Heatley, CH Kok, ... Australian Society for Medical Research SA Meeting 2018, 2018 | | 2018 |
| Identification and characterisation of ruxolitinib resistant mutations in pro-B cell model of high-risk acute lymphoblastic leukaemia CEJ Downes, BJ McClure, B Mayne, JB Bruning, S Heatley, C Kok, ... Australasian Genomic Technologies Association (AGTA) 2018 Annual Conference, 2018 | | 2018 |
| Identification and cloning of a novel GOLGA4-JAK2 fusion from an adult patient with B-cell acute lymphoblastic leukaemia CEJ Downes, BJ McClure, S Heatley, T Sadras, TP Hughes, CH Kok, ... Australian Society for Medical Research (ASMR) SA Meeting 2017, 2017 | | 2017 |
